Skip to main content
Erschienen in: Pathology & Oncology Research 3/2017

30.12.2016 | Original Article

Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients

verfasst von: Kinga Tóth, Árpád V. Patai, Alexandra Kalmár, Barbara Kinga Barták, Zsófia Brigitta Nagy, Orsolya Galamb, Barnabás Wichmann, Zsolt Tulassay, Béla Molnár

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

To determine the level of cell-free DNA (cfDNA), Septin 9 (SEPT9) and tumor markers (CEA, AFP, CA19–9, TPA, CA72–4). Plasma samples were collected four times a day (06:00, 12:00, 18:00, 24:00) from 9 patients with CRC (5 stage I-II, 4 stage III-IV), from one with colorectal adenoma and from one healthy control. CfDNA was isolated, quantified and bisulfite-converted. CfDNA and methylated SEPT9 were determined by RT-PCR. Plasma levels of conventional tumor markers were also measured. The lowest cfDNA concentrations were observed at 24:00 and 18:00 in stage I-III patients. In stage IV samples low cfDNA level (mean 48.2 ng/ml) were observed at several time points (6:00, 12:00, 18:00). The highest cfDNA levels were measured at 6:00 and 12:00 in CRC I-III stages and at 24:00 in stage IV samples (78.65 ng/ml). Higher in-day differences were found in stage II (43–48%) than in stage I samples (22%). Interestingly, the highest SEPT9 methylation level was found at 24:00 in most CRC cases, in contrast to the cfDNA levels. At 24:00, all cancer and adenoma cases were positive for SEPT9 methylation. At other time points (6:00, 12:00, 18:00) only 77.7% of CRC samples showed SEPT9 positivity. Stage I samples were SEPT9 positive only at 24:00. CEA and CA19–9 levels displayed correlation with the amount of cfDNA in case of late stage cases. Daytime activity can influence SEPT9 positivity in cases with low concentration of cfDNA. Thus, it may improve screening sensitivity by collecting samples earlier in the morning.
Literatur
2.
Zurück zum Zitat Mandel P, Métais P (1948) Nucleic acids in human blood plasma. C R Acad Sci Paris 15:241–243 Mandel P, Métais P (1948) Nucleic acids in human blood plasma. C R Acad Sci Paris 15:241–243
3.
Zurück zum Zitat Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 15:646–650 Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 15:646–650
4.
Zurück zum Zitat Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 15:318–322. doi:10.1159/000226740 Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 15:318–322. doi:10.​1159/​000226740
5.
Zurück zum Zitat Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 15:1659–1665 Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 15:1659–1665
8.
Zurück zum Zitat Fatouros IG, Destouni A, Margonis K, Jamurtas AZ, Vrettou C, Kouretas D, Mastorakos G, Mitrakou A, Taxildaris K, Kanavakis E, Papassotiriou I (2006) Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. Clin Chem 52:1820–1824. doi:10.1373/clinchem.2006.070417 CrossRefPubMed Fatouros IG, Destouni A, Margonis K, Jamurtas AZ, Vrettou C, Kouretas D, Mastorakos G, Mitrakou A, Taxildaris K, Kanavakis E, Papassotiriou I (2006) Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. Clin Chem 52:1820–1824. doi:10.​1373/​clinchem.​2006.​070417 CrossRefPubMed
12.
Zurück zum Zitat Leung TN, Zhang J, Lau TK, Chan LYS, Lo D (2001) Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 47:137–139PubMed Leung TN, Zhang J, Lau TK, Chan LYS, Lo D (2001) Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 47:137–139PubMed
14.
17.
Zurück zum Zitat Haus E, Smolensky MH (1999) Biologic rhythms in the immune sys-tem. Chronobiol Int 16:581–622CrossRefPubMed Haus E, Smolensky MH (1999) Biologic rhythms in the immune sys-tem. Chronobiol Int 16:581–622CrossRefPubMed
18.
Zurück zum Zitat Born J, Lange T, Hansen K, Molle M, Fehm HL (1997) Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol 158:4454–4464PubMed Born J, Lange T, Hansen K, Molle M, Fehm HL (1997) Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol 158:4454–4464PubMed
19.
Zurück zum Zitat Kawate T, Abo T, Hinuma S, Kumagai K (1981) Studies of the bioperio-dicity of the immune response. II. Co-variations of murine T and B cells and a role of corticosteroid. J Immunol 126:1364–1367PubMed Kawate T, Abo T, Hinuma S, Kumagai K (1981) Studies of the bioperio-dicity of the immune response. II. Co-variations of murine T and B cells and a role of corticosteroid. J Immunol 126:1364–1367PubMed
21.
Zurück zum Zitat Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, Dove WF, Pinto LH, Turek FW, Takahashi JS (1994) Muta-genesis and mapping of a mouse gene, clock, essential for circadian behavior. Science 264:719–725CrossRefPubMedPubMedCentral Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, Dove WF, Pinto LH, Turek FW, Takahashi JS (1994) Muta-genesis and mapping of a mouse gene, clock, essential for circadian behavior. Science 264:719–725CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Lee C, Etchegaray JP, Cagampang FR, Loudon AS, Reppert SM (2001) Posttranslational mechanisms regulate the mammalian circadian clock. Cell 107:855–867CrossRefPubMed Lee C, Etchegaray JP, Cagampang FR, Loudon AS, Reppert SM (2001) Posttranslational mechanisms regulate the mammalian circadian clock. Cell 107:855–867CrossRefPubMed
23.
25.
26.
Zurück zum Zitat Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 93:1563–1568. doi:10.1093/jnci/93.20.1563 CrossRefPubMed Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 93:1563–1568. doi:10.​1093/​jnci/​93.​20.​1563 CrossRefPubMed
27.
Zurück zum Zitat Cash E, Sephton SE, Chagpar AB, Spiegel D, Rebholz WN, Zimmaro LA, Tillie JM, Dhabhar FS (2015) Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. Brain Behav Immun 48:102–114. doi:10.1016/j.bbi.2015.02.017 CrossRefPubMed Cash E, Sephton SE, Chagpar AB, Spiegel D, Rebholz WN, Zimmaro LA, Tillie JM, Dhabhar FS (2015) Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. Brain Behav Immun 48:102–114. doi:10.​1016/​j.​bbi.​2015.​02.​017 CrossRefPubMed
28.
Zurück zum Zitat Focan C, Focan-Henrard D, Collette J, Mechkouri M, Levi F, Hrushesky W, Touitou Y, Franchimont P (1986) Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in humans. Anticancer Res 6:1137–1144PubMed Focan C, Focan-Henrard D, Collette J, Mechkouri M, Levi F, Hrushesky W, Touitou Y, Franchimont P (1986) Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in humans. Anticancer Res 6:1137–1144PubMed
29.
Zurück zum Zitat Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ (2008) Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 23:42–47CrossRefPubMed Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ (2008) Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 23:42–47CrossRefPubMed
30.
Zurück zum Zitat Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, Miehlke S, Stolz T, Model F, Roblick UJ, Bruch HP, Koch R, Liebenberg V, Devos T, Song X, Day RH, Sledziewski AZ, Lofton-Day C (2008) Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 3:e3759. doi:10.1371/journal.pone.0003759 CrossRefPubMedPubMedCentral Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, Miehlke S, Stolz T, Model F, Roblick UJ, Bruch HP, Koch R, Liebenberg V, Devos T, Song X, Day RH, Sledziewski AZ, Lofton-Day C (2008) Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 3:e3759. doi:10.​1371/​journal.​pone.​0003759 CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55:1337–1346. doi:10.1373/clinchem.2008.115808 CrossRefPubMed deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55:1337–1346. doi:10.​1373/​clinchem.​2008.​115808 CrossRefPubMed
34.
Zurück zum Zitat Potter NT, Hurban P, White MN, Whitlock KD, Lofton-Day CE, Tetzner R, Koenig T, Quigley NB, Weiss G (2014) Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem 60:1183–1191. doi:10.1373/clinchem.2013.221044 CrossRefPubMed Potter NT, Hurban P, White MN, Whitlock KD, Lofton-Day CE, Tetzner R, Koenig T, Quigley NB, Weiss G (2014) Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem 60:1183–1191. doi:10.​1373/​clinchem.​2013.​221044 CrossRefPubMed
35.
Zurück zum Zitat Jin P, Kang Q, Wang X, Yang L, Yu Y, Li N, He YQ, Han X, Hang J, Zhang J, Song L, Han Y, Sheng JQ (2014) Performance of a second generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol 30:830–833. doi:10.1111/jgh.12855 CrossRef Jin P, Kang Q, Wang X, Yang L, Yu Y, Li N, He YQ, Han X, Hang J, Zhang J, Song L, Han Y, Sheng JQ (2014) Performance of a second generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol 30:830–833. doi:10.​1111/​jgh.​12855 CrossRef
37.
Zurück zum Zitat Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T, Osborn N, Snover D, Day RW, Ransohoff DF, PRESEPT Clinical Study Steering Committee, Investigators and Study Team (2014) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63:317–325. doi:10.1136/gutjnl-2012-304149 CrossRefPubMed Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T, Osborn N, Snover D, Day RW, Ransohoff DF, PRESEPT Clinical Study Steering Committee, Investigators and Study Team (2014) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63:317–325. doi:10.​1136/​gutjnl-2012-304149 CrossRefPubMed
38.
Zurück zum Zitat Tóth K, Wasserkort R, Sipos F, Kalmár A, Wichmann B, Leiszter K, Valcz G, Juhász M, Miheller P, Patai ÁV, Tulassay Z, Molnár B (2014) Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One 9:e115415. doi:10.1371/journal.pone.0115415 CrossRefPubMedPubMedCentral Tóth K, Wasserkort R, Sipos F, Kalmár A, Wichmann B, Leiszter K, Valcz G, Juhász M, Miheller P, Patai ÁV, Tulassay Z, Molnár B (2014) Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One 9:e115415. doi:10.​1371/​journal.​pone.​0115415 CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P, Andriulli A, Piepoli A (2011) Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int 28:841–851. doi:10.3109/07420528.2011.615182 CrossRefPubMed Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P, Andriulli A, Piepoli A (2011) Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int 28:841–851. doi:10.​3109/​07420528.​2011.​615182 CrossRefPubMed
44.
Zurück zum Zitat Zubelewicz-Szkodzinska B, Muc-Wierzgon M, Wierzgon J, Brodziak A (2001) Dynamics of circadian fluctuations in serum concentration of cortisol and TNF-alpha soluble receptors in gastrointestinal cancer patients. Oncol Rep 8:207–212. doi:10.3892/or.8.1.207 PubMed Zubelewicz-Szkodzinska B, Muc-Wierzgon M, Wierzgon J, Brodziak A (2001) Dynamics of circadian fluctuations in serum concentration of cortisol and TNF-alpha soluble receptors in gastrointestinal cancer patients. Oncol Rep 8:207–212. doi:10.​3892/​or.​8.​1.​207 PubMed
45.
Zurück zum Zitat Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, Jasmin C, Lévi F (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757–1764. doi:10.1158/1078-0432.CCR-04-2000 CrossRefPubMed Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, Jasmin C, Lévi F (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757–1764. doi:10.​1158/​1078-0432.​CCR-04-2000 CrossRefPubMed
46.
Zurück zum Zitat Halberg F, Haus E, Lakatua DJ, Antinozzi R, Cornélissen G (1995) Cancer marker assessment: case report on salivary and urinary CEA. In Vivo 9:311–314PubMed Halberg F, Haus E, Lakatua DJ, Antinozzi R, Cornélissen G (1995) Cancer marker assessment: case report on salivary and urinary CEA. In Vivo 9:311–314PubMed
Metadaten
Titel
Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients
verfasst von
Kinga Tóth
Árpád V. Patai
Alexandra Kalmár
Barbara Kinga Barták
Zsófia Brigitta Nagy
Orsolya Galamb
Barnabás Wichmann
Zsolt Tulassay
Béla Molnár
Publikationsdatum
30.12.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2017
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0174-2

Weitere Artikel der Ausgabe 3/2017

Pathology & Oncology Research 3/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.